Searched for
INDIAN PHARMA INDUSTRY
Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...- Govt outlines next phase of pharma growthThe government highlighted its achievements, reforms, and policy initiatives, aiming to boost exports from $31 billion to $50 billion by 20...
- Betting big on mid and smallcaps; largecaps most expensive on PEG basis, says Dinshaw IraniHelios Mutual Fund is shifting investments from large companies to mid and small companies. This move follows earnings growth trends where ...
- SBI in $1 billion funding for Sun Pharma’s US dealState Bank of India is set to commit up to $1 billion to fund Sun Pharmaceutical Industries Ltd.'s $12 billion acquisition of Organon & Co....
- India willing to open its market to high-quality, innovative pharma products, says commerce ministerIndia is ready to welcome high-quality global pharmaceutical products. This move is in exchange for better market access for Indian drug ex...
- Stock picks of the week; 5 stocks with consistent score improvement and upside potential of up to 25%Even in normal times it is futile to try and guess the outcome of most global events. But in the New World Order, it makes no sense at all ...
- 100 days of Iran war, Rs 4,50,000 crore wiped out: Is your stock portfolio safe from missiles?Indian equities have lost Rs 4.5 lakh crore in 100 days as the Iran-led West Asia conflict and a global AI trade unwind trigger sharp FII o...
- Uzbekistan can provide more incentives to Indian pharma firms, aims to become regional hub for supplyUzbekistan is inviting Indian drug companies to invest more. They are offering better subsidies and technology help. This aims to make Uzbe...
- We expect interest rates to be left the way they are: Ficci chief Anant GoenkaFicci president Anant Goenka advocates for steady interest rates, citing supply-side price pressures from the West Asia crisis. He suggests...
- Pharma exports to US seen muted this yearIndian pharma exports to the US face a subdued outlook this year. Policy uncertainties, falling generic prices, and regional conflicts are ...
- Avammune’s big bet: Why the future of cancer treatment may come in a pillAs global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...
- 'Wait out IT, buy pharma and defence'; Ajay Bagga's 3-sector playbook for 2026Ajay Bagga offers a clear strategy for Indian markets. He advises waiting for real AI revenue in IT. Pharma remains a strong investment due...
- ETMarkets AIF Talk| Returns with liquidity: How Vivriti's semi-liquid debt fund is redefining private credit investing, says Priyam KediaVivriti's Short Term Debt Fund offers private credit-like returns with periodic liquidity, resonating with investors. India's private credi...
- Trade pact with Oman strengthens India's energy security: ExpertsThe recent trade accord between India and Oman represents a significant leap toward energy independence and economic integration. Experts n...
- Palo Alto Networks warns AI-powered cyberattacks could overwhelm enterprises within months: Meerah RajavelPalo Alto Networks warns that advanced AI-powered cyberattacks could become widely accessible within months, significantly lowering the bar...
- Zaynich's blockbuster potential lifts Wockhardt's long-term outlookWockhardt's novel antibiotic, Zaynich, has received USFDA approval after a 12-year effort, sparking hopes for a turnaround after years of n...
- Ahead of Market: 10 things that will decide stock market action on TuesdayBenchmark indices Sensex and Nifty fell for a fourth straight session amid elevated crude oil prices, geopolitical tensions and persistent ...
- Q4 earnings review: Motilal Oswal highlights broad-based beat on estimates, lists 6 sectors that exceeded expectationsMotilal Oswal said Q4 FY26 earnings surpassed expectations, with aggregate profits rising 16% year-on-year against its 8% estimate. Strong ...
- More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...
- Ebola at the gates: Why India must not let its guard downIndia is enhancing its surveillance protocols following an Ebola outbreak in the Democratic Republic of Congo and Uganda. One of two suspec...
Load More
